PATHOLOGY OF ADENOCARCINOMA OF THE PROSTATE--BIOLOGIC BEHAVIOR

我们的目标是开发和测试更好的方法 对前列腺癌的病理进行定量评估，以便 加强对预后的检测和预测。利用各种 图像分析系统与常规组织学的结合 参数，我们将分析1000个完全嵌入的部首 前列腺切除标本。我们的具体目标是：1)前瞻性 核染色质质构分析相结合的评价 形态计量学和DNA倍体作为疾病复发的预测指标 420例晚期前列腺癌患者行前列腺癌根治术 T2B和T2C期前列腺癌；2)既往研究 用于预测前列腺癌进展的未经测试的生物标志物 在根治性前列腺切除术后。包括：1)细胞死亡和 增殖标志物；2)神经内分泌标志物；3)血管生成 标志物；4)脂肪酸合成酶(OA519)；5)bcl2；6)E-钙粘蛋白； 7)8号染色体的荧光原位杂交(FISH)， 8p和8q；3)对染色质纹理的使用进行调查， 核形态计量学和其他各种生物标志物提供 活检材料的预后信息；4)前瞻性 发表在《美国医学会杂志》上的一项研究证实了预测“微不足道”的有效性 根据针刺活检结果和血清与“重大”疾病的对比 未触及的前列腺癌患者的PSA测定；5) 遗传性前列腺癌的病理评价 利用DNA倍性、染色质纹理、血清和组织 生物标志物和核形态计量学；6)临床和病理 对新描述的抗肿瘤单抗进行评估的研究 结合形式和自由形式的PSA，7)计算机辅助的开发 基于客观可再现性的建筑评分系统 量化的肿瘤特征。上述研究的目的将是 区分相对迟缓的前列腺癌 可能会保守地管理那些更具攻击性的人 需要治疗的肿瘤。这个问题变得越来越重要， 通过早期的筛选技术进行增强的检测 生物恶性程度不明的前列腺癌。对…的预测 肿瘤进展几率较高的患者也会 是实施辅助治疗所必需的。

Our objective is to develop and test better methods of quantitatively evaluating the pathology of prostate cancer so as to enhance detection and prediction of prognosis. Utilizing various image analysis systems in conjunction with routine histologic parameters, we will analyze 1000 totally embedded radical prostatectomy specimens. Our specific aims are: 1) Prospective evaluation of combination of chromatin texture analysis, nuclear morphometry, and DNA ploidy as predictors of disease recurrence following radical prostatectomy in a group of 420 men with stage T2b and stage T2c prostate cancer; 2) Investigation of previously untested biomarkers for prostate cancers to predict progression following radical prostatectomy. These include: 1) cell death and proliferation markers; 2) neuroendocrine markers; 3) angiogenesis markers; 4) fatty acid synthase (OA519); 5) BCL-2; 6) E-cadherin; and 7) fluorescent in situ hybridization (FISH) for chromosomes 8, 8p, and 8q; 3) Investigation of the use of chromatin texture, nuclear morphometry and other various biomarkers to provide prognostic information on biopsy material; 4) Prospective validation of study published in JAMA to predict "insignificant" vs. "significant" disease based on needle biopsy findings and serum PSA measurements in men with non-palpable prostrate cancer; 5) Pathological evaluation of cases of hereditary prostate cancer utilizing DNA ploidy, chromatin texture, serum and tissue biomarkers, and nuclear morphometry; 6) Clinical and pathological studies evaluating the newly described monoclonal antibodies to bound and free forms of PSA, 7) Development of a computer assisted architectural grading system based on objective reproducible quantitative tumor characteristics. The above studies will aim to distinguish relatively indolent prostate cancers which could possibly be managed conservatively from those more aggressive tumors requiring therapy. This issue is increasingly important, with the enhanced detection by screening techniques of earlier prostate cancers of uncertain biologic malignancy. A prediction of patients with a higher probability for tumor progression will also be required for administering of adjuvant therapy.